ReviewCancer communications (London, England)2021
Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?
Review in Cancer communications (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Role of liquid biopsy in the multimodal assessment and treatment of esophageal cancer: a surgical perspective.Updates in surgery · 2026Article
- Prognostic Significance of Circulating Tumor Cells in Patients with Esophageal Cancer Who Attained Pathological Complete Response after Neoadjuvant Therapy.Journal of chest surgery · 2026Article
- Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A multi-center study for colorectal cancer early detection in high-risk disease patients using cell-free fragmentomics assay.Cancer cell international · 2025Article
- Microfluidic Biochip-Based Multiplexed Profiling of Small Extracellular Vesicles Proteins Integrated with Machine Learning for Early Disease Diagnosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- cfDNA hydroxymethylcytosine profiling for detection metastasis and recurrence of Esophageal Squamous Cell Carcinoma.World journal of surgical oncology · 2025Article
- Liquid biopsy in gastrointestinal oncology: clinical applications and translational integration of ctDNA, CTCs, and sEVs.Oncology reviews · 2025Review
- Importance of early detection of esophageal cancer before the tumor progresses too much for effective treatment.World journal of gastrointestinal oncology · 2024Article
- Multimodal analysis of cfDNA methylomes for early detecting esophageal squamous cell carcinoma and precancerous lesions.Nature communications · 2024Article
- Esophageal cancer screening, early detection and treatment: Current insights and future directions.World journal of gastrointestinal oncology · 2024Review
- Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: Results from a retrospective study.The Kaohsiung journal of medical sciences · 2024Article
- Comprehensive analysis of m6A RNA methylation regulators in esophageal carcinoma.Translational cancer research · 2024Article
- Analysis of the primary factors influencing donor derived cell-free DNA testing in kidney transplantation.Frontiers in immunology · 2024Review
- Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer.Cell death & disease · 2023Article
- LINC01305 recruits basonuclin 1 to act on G-protein pathway suppressor 1 to promote esophageal squamous cell carcinoma.Cancer science · 2023Article
- Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma.Frontiers of medicine · 2023Article
- Clinical Utility of Circulating Tumor Cells for Predicting Major Histopathological Response after Neoadjuvant Chemoradiotherapy in Patients with Esophageal Cancer.Journal of personalized medicine · 2022Article
- Liquid Biopsy in Squamous Cell Carcinoma of the Esophagus and of the Head and Neck.Frontiers in medicine · 2022Review
- Weighted Gene Correlation Network Analysis Identifies Specific Functional Modules and Genes in Esophageal Cancer.Journal of oncology · 2021Article
- Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?Cancer communications (London, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer (EC) is a common cancer and is histopathologically classified into esophageal squamous cell carcinoma and esophageal adenocarcinoma. EC is a worldwide public health issue because of late diagnosis and lack of effective therapy. In contrast to standard tumor biopsies, liquid biopsies are emerging as a tool which is minimally invasive that can complement or even substitute more classical approaches. Specifically, cell-free DNA (cfDNA) has shown promise in cancer-related clinical applications. Indeed, cfDNA has been shown to be an effective circulating biomarker for non-invasive cancer diagnosis and monitoring of cancer patients. Although the clinical application of cfDNA has been reported on other cancers, few studies have evaluated its use in EC. Here, we review this relevant literature and discuss limitations and advantages of its application in the diagnosis and monitoring of EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.